Investor Presentaiton

Investor presentation ADA 2019 REFLECT is a RWE trial investigating the safety and efficacy profile of TresibaⓇ for degludec naïve patients with T1D/T2D N=1,267 T1D and T2D patients planned to ReFLECT trial design Degludec QD + standard of care Hypo recor ding Hypo recor Hypo recor ding ding 3 9 Months Months Months initiate degludec Hypo recor ding Hypo recor ding -4 Weeks 12 Key ReFLECT trial inclusion criteria Trial objective To confirm the safety and effectiveness of degludec in patients with T1D or T2D in routine clinical practice Primary endpoint Change in rate of any hypoglycaemia of patients before and after treatment change to degludec People with type 1 and 2 diabetes from 7 countries 0 • T1D and/or T2D adults Male or female > 18 years • Insulin using, planned initiation with degludec No previous use of degludec RWE: real-world evidence; QD: once daily; T1D: type 1 diabetes; T2D: type 2 diabetes Slide 30 novo nordisk

View entire presentation